NIH Clinical Research Studies

Protocol Number: 98-C-0163

Active Accrual, Protocols Recruiting New Patients

Title:
The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-Neoplastic Therapy on Tumor Associated Vasculature
Number:
98-C-0163
Summary:
This is a prospective study to evaluate the use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to assess the effects of agents on tumor associated vasculature. Patients with cancer who are being treated with agents or procedures that may have an effect on the tumor associated vasculature will undergo PET and MRI scans prior to treatment as well as during treatment. PET scans will be used to assess changes in tumor blood flow, blood volume and glucose uptake while MRI will be used to assess changes in tumor vascular density. Findings by PET and MRI will be correlated with standard imaging techniques such as CT scan. This protocol will only be utilized in conjunction with other approved protocols that are evaluating agents or therapies with potential effects on tumor associated vasculature.
Sponsoring Institute:
National Cancer Institute (NCI)
Recruitment Detail
Type: Active Accrual Of New Subjects
Gender: Male & Female
Referral Letter Required: No
Population Exclusion(s): None

Eligibility Criteria:
INCLUSION CRITERIA:

All patients greater than 18 years old who are eligible for a treatment protocol evaluating a therapeutic modality which may have an effect on tumor associated vasculature.

Patients must have imageable disease by standard CT or MRI and at least one lesion measuring greater than 2 cm in diameter.

Patients must be willing to return to NIH for their imaging scans.

Patients must be able to sign informed consent.

EXCLUSION CRITERIA:

Patients must weigh greater than 136 kgs, which is the weight limit for the scanner tables.

Pregnancy or breast-feeding. A negative pregnancy test (urine or serum) is required prior to enrollment.

Renal insufficiency as determined by a serum creatinine greater than 2.0.

History of sensitivity to contrast agents which cannot be controlled with premedication

Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices

Special Instructions: Currently Not Provided
Keywords:
Anti-Angiogenesis
Angiogenesis
Noninvasive
Blood
Vessels
Recruitment Keywords:
None
Conditions:
Neoplasm
Investigational Drug(s):
18-FDG
H2O-15
11-CO
Investigational Device(s):
None

Contacts:
CSSC
Clinical Studies Support Center/NCI
164 Rollins Avenue
2nd FLoor
Rockville, MD 20852
Phone: (888) 624-1937
Fax: (301) 881-8239
Electronic Address: ncicssc@mail.nih.gov

Citations:
Significance of angiogenesis in tumour progression and metastasis

The influence of angiogenesis research on management of patients with breast cancer

Clinical applications of research on angiogenesis

Active Accrual, Protocols Recruiting New Patients

If you have:


Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home


Clinical Center LogoWarren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/23/2004

Search The Studies Help Questions